AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9820740 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative (adjuvant/neoadjuvant) chemoradiation regimens
Number of subjects: 0
Study 9820740 — intervention group
Group type: EXPERIMENTAL
Intervention: More aggressive regimens than 5-FU
Number of subjects: 0
Study 9820740 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU based chemoradiation with gemcitabine
Number of subjects: 0
Study 8569517 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-managed delivery unit
Number of subjects: 2844
Study 8569517 — intervention group
Group type: COMPARATOR
Intervention: Consultant-led labour ward
Number of subjects: 2844
Study 2705601 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwritten thank you note at the bottom of the letter
Number of subjects: 604
Study 2705601 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized mailout package
Number of subjects: 604
Study 2705601 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 604
Study 343968 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg fendosal
Number of subjects: 100
Study 343968 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fendosal
Number of subjects: 100
Study 343968 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg aspirin
Number of subjects: 100
Study 343968 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg fendosal
Number of subjects: 100
Study 343968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30084288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 1784
Study 30084288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1784
Study 27503436 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder phone call from a patient service coordinator 7 days prior to appointment
Number of subjects: 2247
Study 27503436 — intervention group
Group type: COMPARATOR
Intervention: Usual care (automated phone call)
Number of subjects: 2247
Study 27503436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (reminder phone call)
Number of subjects: 2247
Study 24512654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose warfarin (test INR 1.5-2.0)
Number of subjects: 375
Study 24512654 — intervention group
Group type: COMPARATOR
Intervention: Standard warfarin (control INR 2.0-3.0)
Number of subjects: 375
Study 22025011 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with flexor carpi radialis ligament reconstruction and interposition and temporary K‐wire stabilization (Group T+LRTI)
Number of subjects: 99
Study 22025011 — intervention group
Group type: COMPARATOR
Intervention: Trapeziectomy with no ligament reconstruction, no soft tissue interposition and no temporary Kirschner wire stabilization (Group T)
Number of subjects: 99
Study 20145259 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-8958 (5, 10, 20, 40, 80, or 120 mg single dose; 20 or 40 mg twice-daily for 3 days)
Number of subjects: 76
Study 20145259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 18398475 — intervention group
Group type: EXPERIMENTAL
Intervention: PfCP‐2.9 vaccine (20, 50, 100, or 200 microg)
Number of subjects: 52
Study 18398475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adjuvant only)
Number of subjects: 52
Study 15743661 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback
Number of subjects: 0
Study 15743661 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational reminder messages
Number of subjects: 0
Study 15743661 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 12512985 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hydrogen peroxide bleaching gel (Rapid White)
Number of subjects: 50
Study 12512985 — intervention group
Group type: COMPARATOR
Intervention: 6% hydrogen peroxide whitening strips (Crest Whitestrips)
Number of subjects: 50
Study 10661672 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement-based intensive outpatient treatment (RBT), n = 28
Number of subjects: 52
Study 10661672 — intervention group
Group type: COMPARATOR
Intervention: Referral to community treatment resources, n = 24
Number of subjects: 52
Study 8839908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2, Vinblastine 6 mg/m2, Ifosfamide 3 mg/m2 i.v. on day 1 every 3 weeks (VIP)
Number of subjects: 212
Study 8839908 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2, Ifosfamide 3 mg/m2, Etoposide 120 mg/m2 on days 1, 2, and 3 (VIP-16)
Number of subjects: 212
Study 1810523 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamic acid suppositories (200 mg) every 12 h during the immediate postsurgical period in gynecological patients.
Number of subjects: 40
Study 1810523 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamic acid (active drug) given to pregnant women.
Number of subjects: 40
Study 1810523 — intervention group
Group type: COMPARATOR
Intervention: Placebo given every 12 h during the immediate postsurgical period in gynecological patients.
Number of subjects: 40
Study 6667652 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematalac
Number of subjects: 9
Study 6667652 — intervention group
Group type: COMPARATOR
Intervention: Premium
Number of subjects: 9
Study 31881984 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supplemental parenteral nutrition on the first day of ICU stay
Number of subjects: 0
Study 31881984 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving supplemental parenteral nutrition on the seventh day of ICU stay
Number of subjects: 0
Study 29653634 — intervention group
Group type: COMPARATOR
Intervention: Loading dose of 80 mg atorvastatin before percutaneous coronary intervention followed by an additional dose of 80 mg 24 hours after the procedure
Number of subjects: 4200
Study 27029553 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement (TKR) followed by non-surgical treatment (neuromuscular exercise, education, diet, insoles, pain medication)
Number of subjects: 100
Study 27029553 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment alone
Number of subjects: 100
Study 25734732 — intervention group
Group type: EXPERIMENTAL
Intervention: Scattered-site housing with Intensive Case Management (ICM) services
Number of subjects: 1198
Study 25734732 — intervention group
Group type: COMPARATOR
Intervention: Usual care (existing housing and support services)
Number of subjects: 1198
Study 25734732 — intervention group
Group type: EXPERIMENTAL
Intervention: Scattered-site housing with ICM services
Number of subjects: 1198
Study 22003960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin supplementation (0.14 + 0.006 mg daily)
Number of subjects: 114
Study 22003960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 19573143 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and prebiotics
Number of subjects: 19
Study 19573143 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 19
Study 18852278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamprenavir-ritonavir (FPV/r) 700/100 mg twice daily
Number of subjects: 113
Study 15678552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced (DCE) MRI
Number of subjects: 25
Study 15678552 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE MRI
Number of subjects: 25
Study 11913610 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive subjects
Number of subjects: 178
Study 11913610 — intervention group
Group type: COMPARATOR
Intervention: Controlled and treated hypertensive subjects
Number of subjects: 178
Study 11913610 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated and uncontrolled hypertensive subjects
Number of subjects: 178
Study 10436256 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyloxymethyl-thiamine (BOM)
Number of subjects: 10
Study 10436256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9422174 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone therapy (Group A)
Number of subjects: 151
Study 9422174 — intervention group
Group type: COMPARATOR
Intervention: No thiopentone therapy (Group B)
Number of subjects: 151
Study 2137344 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 14
Study 6962371 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-restriction group
Number of subjects: 0
Study 6962371 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29737226 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 49
Study 29737226 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nitroglycerin (NTG)
Number of subjects: 49
Study 29737226 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 49
Study 28220279 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR with AV search hysteresis (n=502)
Number of subjects: 1530
Study 28220279 — intervention group
Group type: COMPARATOR
Intervention: VVI programming (n=486)
Number of subjects: 1530
Study 28220279 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study cohort (n=1461)
Number of subjects: 1530
Study 26152298 — intervention group
Group type: EXPERIMENTAL
Intervention: New system of care (structured assessment and treatment algorithms)
Number of subjects: 800
Study 26152298 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 800
Study 26152298 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs of Stroke Care Coordinator inputs
Number of subjects: 800
Study 26152298 — intervention group
Group type: EXPERIMENTAL
Intervention: Total health and social care costs
Number of subjects: 800
Study 26152298 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-adjusted life year gains
Number of subjects: 800
Study 24042012 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training for 24 weeks
Number of subjects: 0
Study 24042012 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study 21088114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 100/50 μg bid (FP200/S100)
Number of subjects: 0
Study 21088114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 μg once daily (CIC160)
Number of subjects: 0
Study 21088114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19770376 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 267
Study 19770376 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemoradiotherapy
Number of subjects: 267
Study 21191076 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC/Hib vaccine coadministered with PCV7 and MMR vaccine
Number of subjects: 0
Study 21191076 — intervention group
Group type: COMPARATOR
Intervention: MCC/Hib vaccine alone followed by PCV7 with MMR vaccine
Number of subjects: 0
Study 16201128 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT1 group; n = 60)
Number of subjects: 120
Study 16201128 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT2 group; n = 60)
Number of subjects: 120
Study 16201128 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT1 group; n = 54)
Number of subjects: 120
Study 16201128 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT2 group; n = 53)
Number of subjects: 120
Study 16201128 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains susceptible to metronidazole
Number of subjects: 120
Study 16201128 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains resistant to metronidazole
Number of subjects: 120
Study 16201128 — intervention group
Group type: EXPERIMENTAL
Intervention: FAT1 group
Number of subjects: 120
Study 16201128 — intervention group
Group type: EXPERIMENTAL
Intervention: FAT2 group
Number of subjects: 120
Study 11966503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine, 0.3 mg
Number of subjects: 10
Study 11966503 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 10
Study 9917050 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-scopolamine
Number of subjects: 50
Study 9917050 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 50
Study 9917050 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 50
Study 7676701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C bound to activated carbon particles (MMC-CH) 50 mg dispersed throughout the peritoneal cavity before surgical closure
Number of subjects: 113
Study 7676701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraperitoneal anticancer drugs)
Number of subjects: 113
Study 1968324 — intervention group
Group type: EXPERIMENTAL
Intervention: azatadine
Number of subjects: 56
Study 1968324 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 56
Study 1968324 — intervention group
Group type: EXPERIMENTAL
Intervention: astemizole
Number of subjects: 56
Study 1968324 — intervention group
Group type: COMPARATOR
Intervention: nothing (control)
Number of subjects: 56
Study 7423159 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (2 x 5000 units subcutaneously/day, first dose 1‐‐2 hours before surgery)
Number of subjects: 41
Study 7423159 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 41
Study 7423159 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and control combined (independently of heparin administration)
Number of subjects: 41
Study 30298667 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, a monoclonal antibody targeting CD20 B-cells
Number of subjects: 0
Study 30298667 — intervention group
Group type: COMPARATOR
Intervention: Daily oral prednisolone
Number of subjects: 0
Study 30298667 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors and cyclophosphamide
Number of subjects: 0
Study 30298667 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab or abatacept
Number of subjects: 0
Study 27742802 — intervention group
Group type: COMPARATOR
Intervention: Cycling (CYC)
Number of subjects: 9
Study 27742802 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided games (SSG)
Number of subjects: 9
Study 25265392 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet counselling aiming for 30 kCal/kg body weight/d and 1.2 g protein/kg/d, face-to-face discussions, 6 interviews during chemotherapy for 3 to 6 months.
Number of subjects: 336
Study 25265392 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 336
Study 25265392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 336
Study 22749425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise intervention (resistance, flexibility, and Kegel exercises) twice a week for 12 weeks
Number of subjects: 66
Study 22749425 — intervention group
Group type: COMPARATOR
Intervention: Kegel exercises (control group)
Number of subjects: 66
Study 20397112 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooibos tea
Number of subjects: 23
Study 20397112 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (6% or 60 grams l(‐1))
Number of subjects: 23
Study 20397112 — intervention group
Group type: COMPARATOR
Intervention: Bottled water (placebo)
Number of subjects: 23
Study 18545916 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 50-100 mg/day
Number of subjects: 15
Study 18545916 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 15
Study 18545916 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 15
Study 15984599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg once daily
Number of subjects: 255
Study 15984599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 12434607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control group (using a special water manometer for cuff pressure control)
Number of subjects: 80
Study 12434607 — intervention group
Group type: COMPARATOR
Intervention: Loose control group (using no leak method of cuff inflation)
Number of subjects: 80
Study 10608206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg x kg(‐1)
Number of subjects: 60
Study 10608206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg x kg(‐1)
Number of subjects: 60
Study 10608206 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.5 mg x kg(‐1) preceded by 0.06 mg x kg(‐1) rocuronium
Number of subjects: 60
Study 8746201 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25, 50, 100 mg
Number of subjects: 10
Study 1675370 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP administered via suction de-epithelialised skin for 4 days
Number of subjects: 7
Study 1675370 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP administered via suction de-epithelialised skin
Number of subjects: 7
Study 1675370 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction de-epithelialisation
Number of subjects: 7
Study 1675370 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin appearance post-treatment
Number of subjects: 7
Study 7393432 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitated depressed patients
Number of subjects: 20
Study 7393432 — intervention group
Group type: EXPERIMENTAL
Intervention: Retarded depressed patients
Number of subjects: 20
Study 7393432 — intervention group
Group type: EXPERIMENTAL
Intervention: Both depressed groups
Number of subjects: 20
Study 7393432 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study 31781230 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinate-based dietary supplement (SBDS; Amberen)
Number of subjects: 227
Study 31781230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 29129157 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy plus standard care
Number of subjects: 206
Study 29129157 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 206
Study 27038287 — intervention group
Group type: EXPERIMENTAL
Intervention: DCorig
Number of subjects: 221
Study 27038287 — intervention group
Group type: EXPERIMENTAL
Intervention: DCsgn
Number of subjects: 221
Study 27038287 — intervention group
Group type: EXPERIMENTAL
Intervention: DCsgn (continuous)
Number of subjects: 221
Study 27038287 — intervention group
Group type: EXPERIMENTAL
Intervention: DCsgn ≤ 5.373 (dichotomous)
Number of subjects: 221
Study 25305235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical root canal treatment
Number of subjects: 48
Study 25305235 — intervention group
Group type: COMPARATOR
Intervention: Single implant treatment
Number of subjects: 48
Study 22520856 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFAs) supplementation
Number of subjects: 73
Study 22520856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 20337988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromoglycate (20 mg inhaled twice daily + before challenge tests)
Number of subjects: 39
Study 20337988 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg inhaled twice daily + before challenge tests)
Number of subjects: 39
Study 20337988 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg orally once daily)
Number of subjects: 39
Study 20337988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (500 microg daily)
Number of subjects: 39
Study 18034853 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD+NBM+PRP
Number of subjects: 26
Study 18034853 — intervention group
Group type: COMPARATOR
Intervention: EMD+NBM
Number of subjects: 26
Study 16613812 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 monotherapy (Group 1, n=42)
Number of subjects: 58
Study 16613812 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 monotherapy subgroup with low‐normal TSH
Number of subjects: 58
Study 16613812 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4+L‐T3 combination therapy (Group 2, n=16)
Number of subjects: 58
Study 16613812 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy women)
Number of subjects: 58
Study 12054094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 12054094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptics
Number of subjects: 0
Study 12054094 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesics
Number of subjects: 0
Study 10099064 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg benazepril (acute dose)
Number of subjects: 21
Study 10099064 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg benazepril (daily for 1 month)
Number of subjects: 21
Study 10099064 — intervention group
Group type: COMPARATOR
Intervention: Baseline FMD
Number of subjects: 21
Study 8147923 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced joint count assessment
Number of subjects: 15
Study 2635094 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily injection of human ultralente
Number of subjects: 20
Study 2635094 — intervention group
Group type: EXPERIMENTAL
Intervention: Two daily injections of human ultralente
Number of subjects: 20
Study 2635094 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily injection of bovine ultralente
Number of subjects: 20
Study 2635094 — intervention group
Group type: EXPERIMENTAL
Intervention: Two daily injections of bovine ultralente
Number of subjects: 20
Study 2635094 — intervention group
Group type: COMPARATOR
Intervention: Human ultralente
Number of subjects: 20
Study 2635094 — intervention group
Group type: COMPARATOR
Intervention: Bovine ultralente
Number of subjects: 20
Study 1057909 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 400 mg/day (S400)
Number of subjects: 38
Study 1057909 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg/day (S200)
Number of subjects: 38
Study 1057909 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 100 mg/day (C100)
Number of subjects: 38